PHY34

TargetMol
Product Code: TAR-T37376
Supplier: TargetMol
CodeSizePrice
TAR-T37376-1mg1mg£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-2mg2mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-5mg5mg£383.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-10mg10mg£534.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-25mg25mg£814.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-50mg50mg£1,083.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-100mg100mg£1,420.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37376-500mg500mg£2,785.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
PHY34 is an inhibitor of late-stage autophagy.1It is cytotoxic to OVCAR-3 and OVCAR-8 ovarian cancer cells (IC50= 4 nM for both) and induces apoptosis in the same cells when used at a concentration of 100 nM. PHY34 increases the number of LC3B puncta and induces autophagosome accumulation in HeLa cells (EC50s = 1.99 and 3.86 nM, respectively). It reduces tumor growth in an OVCAR-8 mouse xenograft model when administered at a dose of 0.75 mg/kg.
CAS:
2130033-55-3
Formula:
C30H30O12
Molecular Weight:
582.6
Pathway:
Autophagy
Purity:
0.98
SMILES:
O=C1C2=C(C3=CC=C(OCO4)C4=C3)C5=CC(OC)=C(OC)C=C5C(O[C@H]6[C@@H]([C@]7([H])[C@](OC(C)(O7)C)([H])[C@H](O6)CO)O)=C2CO1
Target:
Autophagy

References

Young, A.N., Herrera, D., Huntsman, A.C., et al.Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibitionMol. Cancer Ther.17(10)2123-2135(2018)